PPLPHARMA - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 2.8
Show all parameters (20 more)
🏭 Industry
The pharmaceutical sector, particularly the CDMO (Contract Development and Manufacturing Organization) segment, is experiencing a recovery driven by increasing demand for outsourced drug development services, as indicated by MarketsMOJO's report. This growth trend generally benefits companies like Piramal Pharma that operate within this space.
✅ Positive
The company demonstrates a solid capital structure with a low debt-to-equity ratio of 0.10 and consistent profitability, evidenced by PAT growth over the past two quarters. Furthermore, the relatively stable DMA indicators suggest moderate short-term volatility and an established trading range.
⚠️ Limitation
A significant decline in FII holding (-17.7%) coupled with a contraction in DII holding (-1.04%) raises concerns about investor sentiment, which could translate to future earnings quality challenges if not addressed. The sharply reduced PAT Qtr of 113 Cr compared to the previous quarter's 313 Cr suggests a potential deterioration in operational efficiency or increased costs that warrant investigation.
🧾 Long-Term Outlook
We recommend an entry zone around 190-200 ₹, predicated on the current valuation appearing relatively attractive given the industry’s median PE of 34.6 and a PEG ratio of 0.30; however, careful monitoring of investor sentiment regarding FII holdings is crucial. Long-term holding guidance suggests maintaining a position with an eye towards further margin expansion, building operational efficiency to improve profitability, and managing debt levels effectively. The company's overall quality remains acceptable but requires diligent oversight.